CONTINUING MEDICAL EDUCATION
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 4.5 of AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.


WHO SHOULD ATTEND
This educational activity is designed for medical oncologists, radiation oncologists, surgical oncologists, radiologists, pathologists, and other healthcare providers involved or interested in the diagnosis, treatment, and management of solid tumors.


OBJECTIVES
After completing this educational activity, participants should be able to:

- Describe the emerging role of targeted therapies in the treatment of breast cancer, renal cell carcinoma, colorectal cancer, noncolorectal gastrointestinal cancer, lung cancer, head and neck cancer, and malignant melanoma
- Compare and contrast the efficacy and safety of different regimens involving chemotherapy in combination with targeted biologics for solid tumors
- Outline management strategies for breast cancer, renal cell carcinoma, colorectal cancer, noncolorectal gastrointestinal cancer, lung cancer, head and neck cancer, and malignant melanoma in light of the most recent clinical data
- Discuss the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways involved in malignant conditions
- Describe the potential role of immunotherapeutics, targeted agents, and novel chemotherapeutics in the treatment of malignant melanoma and other cancers
- Translate the results of recent clinical trials in solid tumor malignancies and incorporate them into clinical practice

August 23, 2008 Chicago, Illinois

8:30 am
Emerging cytotoxic therapies for breast cancer
Speaker invited

8:50 am
Emerging targeted therapies for breast cancer
Virginia Kaklamani, MD

9:15 am
Case discussion in breast cancer
Virginia Kaklamani, MD

9:30 am
Emerging therapies for head & neck cancer
Everett E. Vokes, MD

10:00 am
Break

10:15 am
Emerging therapies for malignant melanoma
Thomas F. Gajewski, MD, PhD

10:45 am
Emerging therapies for renal cell carcinoma (RCC)
Walter M. Stadler, MD, FACP

11:10 am
Case discussion in RCC
Walter M. Stadler, MD, FACP

11:25 am
Lunch

12:10 pm
Emerging therapies in colorectal cancers
Axel Grothey, MD

12:35 pm
Emerging therapies in noncolorectal gastrointestinal (GI) cancers
Mary F. Mulcahy, MD

1:00 pm
Case discussion in GI cancers
Mary F. Mulcahy, MD

1:15 pm
Emerging therapies in lung cancer
Ravi Salgia, MD, PhD

1:45 pm
Case discussion in lung cancer
Ravi Salgia, MD, PhD

Regular . . . . . . . . . . . . . . . $50.00
Nurses/Fellows* . . . . . . . . $25.00
*proof of eligibility must accompany registration


To Register: You may register online by Monday, August 18, 2008 or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting.

Payment: To pre-register, registration and payment must be received no later than Monday, August 18, 2008. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the meeting is being held as scheduled and not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. An attendee is not registered until full payment is received.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than Monday, August 18, 2008. Substitutions are accepted with written notification. No refunds will be made if received after Monday, August 18.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

 

Chair:
James Epstein, MD
Senior Medical Adviser
Imedex, LLC 


LETTER FROM THE CHAIR:

Dear Colleagues,
It is with great pleasure that I invite you to attend Emerging Therapies in Solid Tumor Oncology, to be held August 23, 2008 in Chicago, Illinois.

This exciting new meeting will take a look at promising new clinical research into oncology solid tumor management and explore how these novel agents and emerging therapies will shape the future of oncology treatment.

Through case discussions and lecture presentations by expert specialists, sessions will highlight the latest scientific findings, representing the most clinically relevant, important developments in oncology research.

We hope you will join us in Chicago for what is sure to be an outstanding interactive event with many lively discussions!

Sincerely,
James M. Epstein, MD
Senior Medical 


CONFERENCE LOCATION AND REGISTRATION
The Fairmont Chicago
200 North Columbus Drive
Chicago, Illinois 60601
Tel.: +1 (312) 565 8000
Fax: +1 (312) 865 1032

The Registration and Information Desk will be staffed:
Saturday, August 23, 2008: 7:00 am – 1:45 pm


ORGANIZER
Imedex
4325 Alexander Drive
Alpharetta, GA 30022-3740 USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

 

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only,and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

© 2008 Imedex, LLC. All rights reserved.
Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty. 

The following companies have provided unrestricted educational grants in support of this Congress:

 

Several options are available to companies interested in supporting this Congress. For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.